<DOC>
	<DOCNO>NCT00034957</DOCNO>
	<brief_summary>The primary goal study evaluate investigational drug 's effectiveness treatment Non small-cell lung cancer ( NSCLC )</brief_summary>
	<brief_title>Study Efficacy Investigational Drug Adult Patients With Non Small-Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Other specific inclusion/exclusion criterion may apply . In order determine eligibility , examination investigator necessary . Eligible patient must least 18 year age diagnosis NSCLC get bad treatment platinumbased chemotherapy . Patients must least one tumor evaluate doctor investigational drug treatment . Any sideeffects prior chemotherapy must subside , blood urine test must show adequate bone marrow , liver , kidney function . Any following exclude patient study participation : receipt 1 prior regimen chemotherapy NSCLC ( repeat chemotherapy different point time count 1 regimen ) . Irradiation 25 % bone marrow , prior high dose chemotherapy bone marrow stem cell support , current participation clinical trial , pregnant breastfeed woman , know HIVpositive AIDSrelated illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Pharmacia</keyword>
</DOC>